Julia Beil

Otfried Müller Str. 10
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Enhanced Antitumor Activity and Induction of Immunogenic Cell Death in NUT Carcinoma Cells by Combining Oncolytic Viruses with the Dual Inhibitor NEO2734.

Enhanced Antitumor Activity and Induction of Immunogenic Cell Death in NUT Carcinoma Cells by Combining Oncolytic Viruses with the Dual Inhibitor NEO2734.

Journal: Viruses

Published: January 15, 2026

An ex vivo permissivity assay to assess replication of the oncolytic virus VSV-GP in patient-derived tumor samples.

An ex vivo permissivity assay to assess replication of the oncolytic virus VSV-GP in patient-derived tumor samples.

Journal: Oncogene

Published: November 04, 2025

The oncolytic vesicular stomatitis virus VSV-GP shows profound oncolytic activity in NUT-carcinoma cell lines.

The oncolytic vesicular stomatitis virus VSV-GP shows profound oncolytic activity in NUT-carcinoma cell lines.

Journal: Molecular therapy. Oncology

Published: July 31, 2025

Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors.

Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors.

Journal: Viruses

Published: April 04, 2024

Efficacy of Different Oncolytic Vaccinia Virus Strains for the Treatment of Murine Peritoneal Mesothelioma.

Efficacy of Different Oncolytic Vaccinia Virus Strains for the Treatment of Murine Peritoneal Mesothelioma.

Journal: Cancers

Published: December 13, 2023

In Vitro Sensitivity of Neuroendocrine Neoplasms to an Armed Oncolytic Measles Vaccine Virus.

In Vitro Sensitivity of Neuroendocrine Neoplasms to an Armed Oncolytic Measles Vaccine Virus.

Journal: Cancers

Published: November 22, 2023

Establishing a New Platform to Investigate the Efficacy of Oncolytic Virotherapy in a Human Ex Vivo Peritoneal Carcinomatosis Model.

Establishing a New Platform to Investigate the Efficacy of Oncolytic Virotherapy in a Human Ex Vivo Peritoneal Carcinomatosis Model.

Journal: Viruses

Published: November 29, 2022

Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma.

Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma.

Journal: Frontiers in oncology

Published: July 16, 2022

Oncolytic viruses: challenges and considerations in an evolving clinical landscape.

Oncolytic viruses: challenges and considerations in an evolving clinical landscape.

Journal: Future oncology (London, England)

Published: July 12, 2022

Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma.

Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma.

Journal: Cancers

Published: May 11, 2022

Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.

Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.

Journal: Viruses

Published: June 02, 2021

Assessing and Overcoming Resistance Phenomena against a Genetically Modified Vaccinia Virus in Selected Cancer Cell Lines.

Assessing and Overcoming Resistance Phenomena against a Genetically Modified Vaccinia Virus in Selected Cancer Cell Lines.

Journal: International journal of molecular sciences

Published: August 05, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026